Advanced preclinical development of a solid tumour-tailored gastric cancer therapy

Antikor Biopharma正在开发一种名为OptiLink的创新药物输送平台。它通过使用寻找肿瘤的抗体来利用免疫系统特异性地向肿瘤传递有效的细胞毒性载荷。与使用完整抗体-药物偶联物（adc）的竞争对手不同，Antikor的技术能够开发出更小的片段-药物偶联物（fdc）。这些产品有许多优点：FDC产品可能具有更高的癌症治疗指数，因为它们更有效，可以更积极地给药，因为它们更快地从正常组织中清除，迅速深入肿瘤，从而更快地破坏肿瘤。Antikor正在开发一种用于胃癌的FDC，有望克服治疗这种疾病的挑战。该项目需要先进的临床前开发和制造工艺优化以及cmo技术转让，以支持未来临床开发的监管提交。

Antikor Biopharma is pioneering an innovative drug delivery platform called OptiLink. It harnesses the immune system by using tumour-seeking antibodies to specifically deliver potent cytotoxic payloads to tumours. Unlike its competitors, who use full antibody-drug conjugates (ADCs), Antikor's technology enables much smaller fragment-drug conjugates (FDCs) to be developed. These have many advantages: FDC products potentially have a higher therapeutic index for cancer therapy as they are more potent, can be dosed more aggressively because they clear from normal tissues more quickly and penetrate rapidly and deeply into tumours, enabling faster tumour destruction. Antikor is developing an FDC for gastric cancer which promises to overcome the challenges in treating this disease. This project entails the advanced preclinical development and manufacturing process optimisation and CMO-technology transfer to support regulatory submissions for future clinical development.